Aliases & Classifications for Eating Disorder

MalaCards integrated aliases for Eating Disorder:

Name: Eating Disorder 12 14
Eating Disorders 52 41 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8670
ICD10 33 F50 F50.9
ICD9CM 35 307.50
NCIt 47 C89332
UMLS 69 C0013473

Summaries for Eating Disorder

MedlinePlus : 41 eating disorders are serious behavior problems. they can include severe overeating or not consuming enough food to stay healthy. they also involve extreme concern about your shape or weight. types of eating disorders include anorexia nervosa, in which you become too thin, but you don't eat enough because you think you are fat bulimia nervosa, which involves periods of overeating followed by purging, sometimes through self-induced vomiting or using laxatives binge-eating, which is out-of-control eating women are more likely than men to have eating disorders. they usually start in the teenage years and often occur along with depression, anxiety disorders, and substance abuse. eating disorders can lead to heart and kidney problems and even death. getting help early is important. treatment involves monitoring, talk therapy, nutritional counseling, and sometimes medicines. nih: national institute of mental health

MalaCards based summary : Eating Disorder, also known as eating disorders, is related to dyspepsia and obsessive-compulsive personality disorder, and has symptoms including adipsia and symptoms concerning nutrition, metabolism, and development. An important gene associated with Eating Disorder is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Ethanol and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and bone, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A specific developmental disorder that is characterized by abnormal eating habits that may involve either insufficient or excessive food intake to the detriment of an individual's physical and emotional health.

Wikipedia : 72 An eating disorder is a mental disorder defined by abnormal eating habits that negatively affect a... more...

Related Diseases for Eating Disorder

Diseases related to Eating Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
id Related Disease Score Top Affiliating Genes
1 dyspepsia 30.4 CCK NPY
2 obsessive-compulsive personality disorder 30.0 BDNF COMT HTR2C SLC6A4
3 personality disorder 27.6 BDNF CCK CNR1 COMT DRD2 HTR2C
4 schizophrenia 27.3 BDNF CCK CNR1 COMT DRD2 HTR2C
5 bulimia nervosa 11.4
6 anorexia nervosa 11.4
7 rumination disorder 11.4
8 borderline personality disorder 10.9
9 autism spectrum disorder 10.9
10 extrapontine myelinolysis 10.8
11 anorexia nervosa 1 10.7
12 obesity, mc4r-related 10.7 GHRL MC4R
13 wernicke-korsakoff syndrome 10.6
14 simple chronic conjunctivitis 10.6 BDNF CNR1
15 mandibular cancer 10.6 CCK GHRL SLC6A4
16 intrahepatic gall duct cancer 10.6 BDNF COMT SLC6A4
17 chronic dacryoadenitis 10.5 BDNF COMT SLC6A4
18 west syndrome 10.5 BDNF CNR1 NPY
19 obesity 10.5
20 rhinoscleroma 10.5 COMT DRD2
21 pica disease 10.5
22 idiopathic juvenile osteoporosis 10.5
23 hypothalamic disease 10.5
24 telogen effluvium 10.5
25 central pontine myelinolysis 10.5
26 brittle diabetes 10.5
27 mbd25-related intellectual disability 10.5
28 cerebral beriberi 10.5
29 korsakoff's amnesic syndrome 10.5
30 ornithosis 10.5 CCK DRD2 SLC6A4
31 cleft lip and palate malrotation cardiopathy 10.5 LEP POMC
32 dementia - subcortical 10.5 CNR1 COMT
33 retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities 10.4 CCK GHRL PYY
34 myositis fibrosa 10.4 CCK PYY SLC6A4
35 postencephalitic parkinson disease 10.4 BDNF DRD2 SLC6A4
36 sweat gland cancer 10.4 CCK PYY SLC6A4
37 ischemic neuropathy 10.4 CCK DRD2 GHRL
38 anosognosia 10.4 COMT DRD2 SLC6A4
39 ulcerative colitis 10.4 BDNF COMT DRD2
40 bladder flat intraepithelial lesion 10.4 BDNF DRD2 SLC6A4
41 intussusception 10.4 ALB CCK
42 adult mesenchymal chondrosarcoma 10.4 POMC SLC6A4
43 hepatic vascular disease 10.4 LEP POMC
44 intracranial cavernous angioma 10.3 DRD2 SLC6A3 SLC6A4
45 conjunctival degeneration 10.3 HTR2C SLC6A4
46 splenic abscess 10.3 DRD2 SLC6A3 SLC6A4
47 pyromania 10.3 DRD2 SLC6A3 SLC6A4
48 eosinophilia-myalgia syndrome 10.3 BDNF DRD2 SLC6A3
49 adrenal cortex disease 10.3 GHRL LEP POMC
50 mediastinum leiomyoma 10.3 ALB GHRL LEP

Graphical network of the top 20 diseases related to Eating Disorder:



Diseases related to Eating Disorder

Symptoms & Phenotypes for Eating Disorder

UMLS symptoms related to Eating Disorder:


adipsia, symptoms concerning nutrition, metabolism, and development

MGI Mouse Phenotypes related to Eating Disorder:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.48 PYY SLC6A3 SLC6A4 ADIPOQ BDNF CCK
2 homeostasis/metabolism MP:0005376 10.47 ADIPOQ ALB BDNF CCK CNR1 COMT
3 growth/size/body region MP:0005378 10.36 ADIPOQ BDNF CNR1 DRD2 HTR2C LEP
4 endocrine/exocrine gland MP:0005379 10.34 SLC6A4 ADIPOQ ALB BDNF CCK COMT
5 adipose tissue MP:0005375 10.32 NPY POMC PYY ADIPOQ CNR1 DRD2
6 nervous system MP:0003631 10.28 SLC6A3 SLC6A4 BDNF CCK CNR1 COMT
7 mortality/aging MP:0010768 10.24 DRD2 HTR2C LEP LEPR POMC SLC6A3
8 integument MP:0010771 10.22 SLC6A4 ADIPOQ BDNF CNR1 DRD2 HTR2C
9 digestive/alimentary MP:0005381 10.17 LEPR NPY ALB BDNF CNR1 DRD2
10 liver/biliary system MP:0005370 10.11 ADIPOQ ALB DRD2 LEP LEPR MC4R
11 normal MP:0002873 10.11 ALB BDNF CNR1 DRD2 GHRL LEPR
12 muscle MP:0005369 10.08 ADIPOQ ALB DRD2 HTR2C LEP LEPR
13 neoplasm MP:0002006 10 ADIPOQ ALB DRD2 LEP LEPR MC4R
14 no phenotypic analysis MP:0003012 9.95 BDNF CCK CNR1 DRD2 LEPR MC4R
15 renal/urinary system MP:0005367 9.92 ADIPOQ ALB COMT DRD2 LEP LEPR
16 reproductive system MP:0005389 9.86 BDNF CNR1 COMT DRD2 LEP LEPR
17 respiratory system MP:0005388 9.7 ADIPOQ BDNF COMT DRD2 LEP LEPR
18 skeleton MP:0005390 9.61 ADIPOQ CNR1 DRD2 LEP LEPR MC4R
19 taste/olfaction MP:0005394 8.92 DRD2 SLC6A3 BDNF CNR1

Drugs & Therapeutics for Eating Disorder

Drugs for Eating Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 386)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
2
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
3
Topiramate Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 97240-79-4 5284627
4
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
5
Memantine Approved, Investigational Phase 4 19982-08-2 4054
6
Amphetamine Approved, Illicit Phase 4 300-62-9 5826 3007
7
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
8
Norepinephrine Approved Phase 4 51-41-2 439260
9
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 16590-41-3 5360515
10
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
11
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
12
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
13
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
14
Baclofen Approved Phase 4 1134-47-0 2284
15
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
16
Dexlansoprazole Approved Phase 4 138530-94-6, 103577-45-3 9578005
17
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
18
Exenatide Approved, Investigational Phase 4,Phase 3 141758-74-9 15991534
19
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
20
Metformin Approved Phase 4,Early Phase 1 657-24-9 14219 4091
21
Clozapine Approved Phase 4 5786-21-0 2818
22
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
23
Pramipexole Approved, Investigational Phase 4,Phase 3 104632-26-0 59868 119570
24
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
25
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
26
Zinc Approved Phase 4,Phase 1,Phase 2 7440-66-6 32051 23994
27
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
28
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
29
Cyproheptadine Approved Phase 4 129-03-3 2913
30
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
31 Zinc sulfate Approved Phase 4 7733-02-0
32
Calcium acetate Approved Phase 4 62-54-4
33
Sevelamer Approved Phase 4 52757-95-6, 152751-57-0 3085017
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
35
Clopidogrel Approved, Nutraceutical Phase 4 120202-66-6, 113665-84-2 60606
36
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
37
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
38 Raclopride Investigational Phase 4 84225-95-6
39 Mosapride Investigational Phase 4 112885-41-3
40
Angiotensin II Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
41 Micronutrients Phase 4,Phase 3,Phase 1,Phase 2
42 Trace Elements Phase 4,Phase 3,Phase 1,Phase 2
43 Vitamin B Complex Phase 4
44 Vitamins Phase 4,Phase 3
45 Antipsychotic Agents Phase 4,Phase 3,Phase 2
46 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
47 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
48 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
49 Tranquilizing Agents Phase 4,Phase 3,Phase 2
50 Analgesics Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 836)

id Name Status NCT ID Phase Drugs
1 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
2 An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder Completed NCT00330655 Phase 4 memantine
3 Folic Acid Supplementation in Eating Disorder Completed NCT01493674 Phase 4
4 Effectiveness of Binge Eating Disorder Treatments Completed NCT00060762 Phase 4
5 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
6 Atomoxetine in the Treatment of Binge Eating Disorder Completed NCT00327834 Phase 4 atomoxetine
7 Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression Completed NCT00607789 Phase 4 Duloxetine;Placebo
8 Antidepressant Safety in Kids Study Completed NCT00395213 Phase 4 Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications
9 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
10 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
11 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
12 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
13 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
14 Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese Completed NCT01739049 Phase 4 Liraglutide
15 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
16 The Effects of Body Contouring: Abdominoplasty and Liposuction Completed NCT02151799 Phase 4
17 Baclofen for Rumination Completed NCT03113396 Phase 4 Baclofen;Placebo oral capsule
18 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
19 Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children Completed NCT02187952 Phase 4
20 Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
21 Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults Completed NCT02706067 Phase 4 Orlistat
22 Near Infrared Spectroscopy (NIRS) and Superior Mesenteric Artery (SMA) Doppler Patterns as Predictor of Feeding Tolerance in Very Low Birth Weight (VLBW) IntraUterine Growth Restricted (IUGR) and NON IUGR Infants Completed NCT01341236 Phase 4
23 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
24 Physical and Chemical Study of Atherosclerosis Mechanisms Completed NCT01700075 Phase 4 Conventional treatment
25 The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents Completed NCT02365025 Phase 4
26 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed NCT00982020 Phase 4 Olanzapine
27 Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia Completed NCT00981526 Phase 4 Telmisartan;Placebo;Clozapine;Olanzapine
28 Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment Completed NCT00651183 Phase 4 Pramipexole immediate release
29 Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF. Recruiting NCT02359513 Phase 4 Antidepressants;Positron Emission Tomography (PET)
30 Does the Advice to Eat a Mediterranean Diet With Low Carbohydrate Intake, Compared With a Low-fat Diet, Reduce Diabetes and Cardiovascular Disease? Recruiting NCT02938832 Phase 4
31 Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease Recruiting NCT03159091 Phase 4 Rengalin;Placebo
32 Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease Recruiting NCT00862446 Phase 4 Omegaven
33 The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS Recruiting NCT03151005 Phase 4 Metformin-GLP-1 Receptor Agonist;Metformin-Oral Contraceptive(OC)
34 Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs Recruiting NCT02515773 Phase 4 Metformin
35 Lifestyle Modification and Liraglutide Active, not recruiting NCT02911818 Phase 4 Liraglutide 3.0mg
36 Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders Not yet recruiting NCT02568007 Phase 4 Cyproheptadine
37 Effect of Zinc Supplementation on Appetite and Growth in Primary Malnourished Children Not yet recruiting NCT03098810 Phase 4 Zinc sulphate
38 Liraglutide Effects on Epicardial Fat Inflammatory Genes Not yet recruiting NCT03260881 Phase 4 Liraglutide Pen Injector [Victoza];matching liraglutide-placebo pre-filled pens
39 Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4 Terminated NCT01277497 Phase 4 Sevelamer carbonate;Calcium acetate
40 Studying the Effects of Sibutramine on Eating Behavior Terminated NCT01170364 Phase 4 Sibutramine;Placebo
41 Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
42 Topiramate Augmentation in Bulimia Nervosa Partial Responders Withdrawn NCT00988481 Phase 4 Topiramate
43 Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
44 Improving Patient Outcome in Group Therapy for Eating Disorders Unknown status NCT01693237 Phase 2, Phase 3
45 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
46 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
47 ARIpiprazole in Anorexia NErvosa Unknown status NCT01082848 Phase 3 aripiprazole;placebo
48 Feeding Education in Patients Submitted to Coronary Angioplasty Unknown status NCT01028066 Phase 3
49 Probiotics in GastroIntestinal Disorders Unknown status NCT00510978 Phase 2, Phase 3
50 Occlusal Splint and Counseling to Temporomandibular Disorder Unknown status NCT01544439 Phase 3

Search NIH Clinical Center for Eating Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Eating Disorder

Anatomical Context for Eating Disorder

MalaCards organs/tissues related to Eating Disorder:

39
Brain, Heart, Bone, Kidney, Liver, Testes, Endothelial

Publications for Eating Disorder

Articles related to Eating Disorder:

(show top 50) (show all 961)
id Title Authors Year
1
Prevalence and correlates of binge eating disorder related features in the community. ( 27899295 )
2017
2
The impact of early shame memories in Binge Eating Disorder: The mediator effect of current body image shame and cognitive fusion. ( 28890226 )
2017
3
'I can't accept that feeling': Relationships between interoceptive awareness, mindfulness and eating disorder symptoms in females with, and at-risk of an eating disorder. ( 27915166 )
2017
4
Female athlete experiences of seeking and receiving treatment for an eating disorder. ( 28051927 )
2017
5
A systematic review and narrative synthesis of interventions for uncomplicated obesity: weight loss, well-being and impact on eating disorder. ( 28889945 )
2017
6
Adolescent and young adult women's opinions of common eating disorder prevention messages. ( 28059633 )
2017
7
Addison's Disease and Possible Cannabis Withdrawal Syndrome Presenting as an Eating Disorder in a Thirty-Year-Old Female. ( 28348901 )
2017
8
Rumination in Patients with Binge-Eating Disorder and Obesity: Associations with Eating-Disorder Psychopathology and Weight-bias Internalization. ( 28078784 )
2017
9
Impaired cortisol awakening response in eating disorder women with childhood trauma exposure: evidence for a dose-dependent effect of the traumatic load. ( 28847330 )
2017
10
Correlates of weight-related quality of life among individuals with binge eating disorder before and after cognitive behavioral therapy. ( 28843136 )
2017
11
Commentary on Phillipou et al. (2017), Anorexia nervosa: Eating disorder or body image disorder? ( 28876079 )
2017
12
Autonomy support and autonomous motivation in the outpatient treatment of adults with an eating disorder. ( 28842966 )
2017
13
Explicit and Implicit Approach vs. Avoidance Tendencies towards High vs. Low Calorie Food Cues in Patients with Obesity and Active Binge Eating Disorder. ( 28953225 )
2017
14
Age effects in eating disorder baseline risk factors and prevention intervention effects. ( 28861902 )
2017
15
Experiential avoidance, eating expectancies, and binge eating: A preliminary test of an adaption of the Acquired Preparedness Model of eating disorder risk. ( 28947185 )
2017
16
Mitochondrial Neurogastrointestinal Encephalomyopathy in the Differential Diagnosis of Eating Disorders. ( 28935389 )
2017
17
A systematic review and secondary data analysis of the interactions between the serotonin transporter 5-HTTLPR polymorphism and environmental and psychological factors in eating disorders. ( 27701012 )
2017
18
Military-related trauma is associated with eating disorder symptoms in male veterans. ( 28940217 )
2017
19
A controlled trial of a yoga-based prevention program targeting eating disorder risk factors among middle school females. ( 28929940 )
2017
20
Treating the binge or the (fat) body? Representations of fatness in a gold standard psychological treatment manual for binge eating disorder. ( 28064539 )
2017
21
Molecular bases of anorexia nervosa, bulimia nervosa and binge eating disorder: shedding light on the darkness. ( 28762842 )
2017
22
Predictors of comorbid eating disorders and association with other obsessive-compulsive spectrum disorders in trichotillomania. ( 28667830 )
2017
23
Eating Disorder Examination Questionnaire (EDE-Q) and Clinical Impairment Assessment (CIA): clinical norms and functional impairment in male and female adults with eating disorders. ( 28084126 )
2017
24
Severity of Binge-Eating Disorder and Its Effects on Treatment Outcome. ( 28858448 )
2017
25
Virtual Reality as a Promising Strategy in the Assessment and Treatment of Bulimia Nervosa and Binge Eating Disorder: A Systematic Review. ( 28698483 )
2017
26
Female Athlete Triad: Future Directions for Energy Availability and Eating Disorder Research and Practice. ( 28886821 )
2017
27
Evidence for ERP biomarkers of eating disorder symptoms in women. ( 28057515 )
2017
28
Visual Attention to Ambiguous Emotional Faces in Eating Disorders: Role of Alexithymia. ( 28762613 )
2017
29
The moderating role of emotional reactivity in the link between parental hostility and eating disorder symptoms in early adolescence. ( 28876200 )
2017
30
A Randomised Controlled Comparison of Second-Level Treatment Approaches for Treatment-Resistant Adults with Bulimia Nervosa and Binge Eating Disorder: Assessing the Benefits of Virtual Reality Cue Exposure Therapy. ( 28804985 )
2017
31
Predicting intolerance of uncertainty in individuals with eating disorder symptoms. ( 28883918 )
2017
32
Associations between eating disorder related symptoms and participants' utilization of an individualized Internet-based prevention and early intervention program. ( 28921689 )
2017
33
Pornography use in sexual minority males: Associations with body dissatisfaction, eating disorder symptoms, thoughts about using anabolic steroids and quality of life. ( 28891676 )
2017
34
Increasing body image flexibility in a residential eating disorder facility: Correlates with symptom improvement. ( 28929944 )
2017
35
Fat mass and obesity-associated gene (FTO) is associated to eating disorders susceptibility and moderates the expression of psychopathological traits. ( 28282466 )
2017
36
Response to the best available treatment for bulimia nervosa and binge-eating disorder is disease severity-dependent. ( 28707477 )
2017
37
Attention-deficit/hyperactivity disorder symptoms and psychological comorbidity in eating disorder patients. ( 28534123 )
2017
38
Intermittent explosive disorder and eating disorders: Analysis of national comorbidity and research samples. ( 28324677 )
2017
39
Psychiatric comorbidity and maternal distress among adolescent eating disorder patients: A comparison with substance use disorder patients. ( 28039823 )
2017
40
Social phobia, depression and eating disorders during middle adolescence: longitudinal associations and treatment seeking. ( 28868945 )
2017
41
Fifty years of anorexia nervosa and other eating disorders in the Australian & New Zealand Journal of Psychiatry. ( 28521537 )
2017
42
New Horizons in Measurement: a Review of Novel and Innovative Approaches to Eating-Disorder Assessment. ( 28891029 )
2017
43
A family-based association study of the HTR1B gene in eating disorders. ( 27579596 )
2016
44
Eating disorder symptoms among undergraduate and graduate students at 12 U.S. colleges and universities. ( 28040637 )
2016
45
Sleep related eating disorder: Importance of prebariatric evaluation-A case report. ( 27614949 )
2016
46
Development and Psychometric Validation of the EDE-QS, a 12 Item Short Form of the Eating Disorder Examination Questionnaire (EDE-Q). ( 27138364 )
2016
47
Emotion regulation difficulties in binge eating disorder with and without the overvaluation of weight and shape. ( 27631564 )
2016
48
A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. ( 26942768 )
2016
49
Eating disorder severity and functional impairment: moderating effects of illness duration in a clinical sample. ( 27659175 )
2016
50
REbeL Peer Education: A model of a voluntary, after-school program for eating disorder prevention. ( 27593168 )
2016

Variations for Eating Disorder

Expression for Eating Disorder

Search GEO for disease gene expression data for Eating Disorder.

Pathways for Eating Disorder

Pathways related to Eating Disorder according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 CCK CNR1 DRD2 GHRL HTR2C LEP
2 12.27 CNR1 COMT NPY POMC
3
Show member pathways
11.97 BDNF DRD2 GHRL NPY
5
Show member pathways
11.72 BDNF DRD2 SLC6A3
6
Show member pathways
10.97 LEP LEPR POMC
7
Show member pathways
10.86 COMT SLC6A3 SLC6A4
8 10.86 ADIPOQ LEP LEPR NPY POMC
9 10.66 MC4R POMC
10 10.52 CCK CNR1

GO Terms for Eating Disorder

Cellular components related to Eating Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 ADIPOQ ALB CCK GHRL LEP NPY
2 extracellular region GO:0005576 9.65 ADIPOQ ALB BDNF CCK GHRL LEP
3 axon GO:0030424 9.1 CCK CNR1 COMT DRD2 GHRL SLC6A3

Biological processes related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 44)
id Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.88 ADIPOQ DRD2 LEP SLC6A4
2 response to drug GO:0042493 9.88 ADIPOQ COMT DRD2 HTR2C SLC6A3 SLC6A4
3 neuropeptide signaling pathway GO:0007218 9.86 NPY POMC PYY
4 locomotory behavior GO:0007626 9.84 DRD2 HTR2C SLC6A3
5 circadian rhythm GO:0007623 9.83 ADIPOQ LEP SLC6A4
6 regulation of blood pressure GO:0008217 9.8 LEP NPY POMC
7 glucose metabolic process GO:0006006 9.79 ADIPOQ GHRL LEP
8 response to nutrient GO:0007584 9.76 ADIPOQ CNR1 LEP SLC6A4
9 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.74 CNR1 DRD2 MC4R
10 response to nicotine GO:0035094 9.72 CNR1 DRD2 SLC6A3
11 response to cocaine GO:0042220 9.71 CNR1 DRD2 SLC6A3
12 positive regulation of multicellular organism growth GO:0040018 9.7 DRD2 GHRL SLC6A3
13 response to iron ion GO:0010039 9.69 DRD2 SLC6A3
14 negative regulation of gluconeogenesis GO:0045721 9.68 ADIPOQ LEPR
15 dopamine metabolic process GO:0042417 9.68 COMT DRD2
16 neurotransmitter biosynthetic process GO:0042136 9.68 SLC6A3 SLC6A4
17 central nervous system neuron development GO:0021954 9.68 LEP NPY
18 ammonium transmembrane transport GO:0072488 9.67 SLC6A3 SLC6A4
19 prepulse inhibition GO:0060134 9.67 DRD2 SLC6A3
20 regulation of synaptic transmission, GABAergic GO:0032228 9.67 CNR1 DRD2
21 negative regulation of blood pressure GO:0045776 9.67 ADIPOQ CNR1 DRD2
22 behavior GO:0007610 9.66 HTR2C NPY
23 sexual reproduction GO:0019953 9.65 LEP LEPR
24 leptin-mediated signaling pathway GO:0033210 9.65 LEP LEPR
25 response to ethanol GO:0045471 9.65 ADIPOQ CNR1 DRD2 LEP SLC6A3
26 positive regulation of growth hormone secretion GO:0060124 9.64 DRD2 GHRL
27 adenohypophysis development GO:0021984 9.64 DRD2 SLC6A3
28 negative regulation of appetite GO:0032099 9.63 CCK LEP
29 monoamine transport GO:0015844 9.63 SLC6A3 SLC6A4
30 dopamine catabolic process GO:0042420 9.62 COMT SLC6A3
31 response to nutrient levels GO:0031667 9.61 ADIPOQ LEP
32 energy reserve metabolic process GO:0006112 9.61 LEP LEPR MC4R
33 regulation of bone remodeling GO:0046850 9.6 LEP LEPR
34 dopamine uptake involved in synaptic transmission GO:0051583 9.59 SLC6A3 SLC6A4
35 regulation of metabolic process GO:0019222 9.58 LEP MC4R
36 positive regulation of appetite GO:0032100 9.56 GHRL NPY
37 adult feeding behavior GO:0008343 9.54 GHRL LEP NPY
38 negative regulation of dopamine secretion GO:0033602 9.51 CNR1 DRD2
39 regulation of feeding behavior GO:0060259 9.5 CNR1 LEPR MC4R
40 bone growth GO:0098868 9.48 LEP LEPR
41 glucose homeostasis GO:0042593 9.46 ADIPOQ CNR1 LEP LEPR
42 feeding behavior GO:0007631 9.35 DRD2 HTR2C MC4R NPY PYY
43 regulation of appetite GO:0032098 8.92 HTR2C NPY POMC PYY
44 G-protein coupled receptor signaling pathway GO:0007186 10.17 CNR1 DRD2 GHRL HTR2C MC4R PYY

Molecular functions related to Eating Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.8 ADIPOQ DRD2 LEP NPY POMC SLC6A3
2 G-protein coupled receptor binding GO:0001664 9.56 GHRL NPY POMC PYY
3 neurotransmitter:sodium symporter activity GO:0005328 9.46 SLC6A3 SLC6A4
4 dopamine binding GO:0035240 9.43 DRD2 SLC6A3
5 monoamine transmembrane transporter activity GO:0008504 9.4 SLC6A3 SLC6A4
6 dopamine:sodium symporter activity GO:0005330 9.37 SLC6A3 SLC6A4
7 drug binding GO:0008144 9.35 ALB CNR1 DRD2 HTR2C SLC6A3
8 neuropeptide hormone activity GO:0005184 9.33 CCK NPY PYY
9 hormone activity GO:0005179 9.17 ADIPOQ CCK GHRL LEP NPY POMC

Sources for Eating Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....